Daniel P. Petrylak, MD, discusses the results of the phase II STRIDE study in metastatic castration-resistant prostate cancer (mCRPC).
Clinical Pearls
Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses the results of thephase II STRIDE studyin metastatic castration-resistant prostate cancer (mCRPC).
The STRIDE study evaluated concurrent versus sequential enzalutamide in combination with sipuleucel-T for mCRPC.
There was no difference seen in immune parameters when comparing early and delayed enzalutamide. The prime-boost effect was similar in the two arms.
Anecdotally, no additive or synergistic toxicities were observed. Full toxicity data will be reported later.
